Sun Pharma sets ₹10,000 cr bond refinancing plan
pre-market1 source ↓machine-written, see hownot a recommendation
- SUNPHARMA close
- ₹1,743
- On the day
- -0.90%
- Futures OI, long unwinding
- -0.0%
- Put-call ratio
- 0.75
- Max pain
- ₹1,780
Sun Pharmaceutical Industries plans to raise up to ₹10,000 cr through two rupee bond tranches to partly refinance the dollar bridge loan used for its acquisition of Organon. The proposed issue includes a ₹3,000 cr greenshoe option, with bids invited from bankers and investors on 23 Oct 2026. The new report describes the structure as five-year and one-day bonds, while the final allocation and terms remain subject to investor demand 💊.
The first tranche is planned at up to ₹3,000 cr and carries a put option at the end of 17 months. The second tranche has a base size of at least ₹5,000 cr, with a ₹2,000 cr greenshoe, and follows a bullet maturity structure. The reported annual coupons are 8.05% and 8.20%. Replacing short-term acquisition funding with longer-dated rupee debt extends the repayment profile but adds interest costs in the company’s domestic funding currency. The company did not respond to the publication’s request for comment.
The refinancing matters for the pharma company because the final issue size, maturity terms and use of proceeds will determine how the Organon acquisition affects leverage and financing expenses. It also shows how large strategic acquisitions can continue to influence balance-sheet decisions after completion. The debt issue is not itself evidence of the final earnings impact, which depends on the bridge-loan repayment and the cost of the new bonds 🤝.
OI Charts data for 19 Oct 2026 showed the shares at ₹1,743, down 0.9% on the day, with volume of 829,445. The stock had declined 5.1% over 20 sessions and traded below its 52-week high of ₹2,047 recorded on 31 Jul 2026. Futures open interest stood at 17,049,200 contracts and showed long unwinding, while the futures premium was 0.02% and the put-call ratio was 0.75.
For the 27 Oct 2026 expiry, max pain stood at ₹1,780. The largest call open interest was at ₹1,760 and the largest put open interest at ₹1,780, placing these levels near the current positioning walls. Traders will watch the bond bidding on 23 Oct, the final pricing and issue size, and disclosures on the bridge loan and post-transaction leverage
Source: Medical Dialogues, 20 Oct 2026
Not investment advice. For informational purposes only.